Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.

被引：2
|
作者：
Kawamoto, Yasuyuki
Meguro, Takashi
Yuki, Satoshi
Nakatsumi, Hiroshi
Sasaki, Takahide
Hatanaka, Kazuteru
Uebayashi, Minoru
Iwanaga, Ichiro
Abe, Nobuhiko
Nakamura, Michio
Okuda, Hiroyuki
Eto, Kazunori
Oba, Ayane
Abe, Masakazu
Oba, Koji
Satoh, Taroh
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
机构：
[1] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[2] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan
[4] Hokkaido Gastroenterol Hosp, Dept Intenal Med, Sapporo, Hokkaido, Japan
[5] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[6] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Med Oncol, Kitami, Hokkaido, Japan
[8] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan
[9] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[10] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[12] Iwamizawa Municipal Gen Hosp, Dept Gastroenterol, Iwamizawa, Japan
[13] Sapporo Kosei Gen Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[14] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan
[15] Univ Tokyo, Interfac Initiat Informat Studies, Tokyo, Japan
[16] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[17] Misawa City Hosp, Misawa, Japan
[18] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [42] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [43] A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5)
    Sakai, Daisuke
    Satoh, Taroh
    Kurokawa, Yukinori
    Kudo, Toshihiro
    Nishikawa, Kazuhiro
    Oka, Yoshio
    Tsujinaka, Toshimasa
    Shimokawa, Toshio
    Doki, Yuichiro
    Furukawa, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (08) : 838 - 840
  • [44] Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
    Ring, Alistair
    Wheatley, Duncan
    Hatcher, Helen
    Laing, Robert
    Plummer, Ruth
    Uttenreuther-Fischer, Martina
    Temple, Graham
    Pelling, Katy
    Schnell, David
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2737 - 2744
  • [45] NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer
    Holden, Joanne
    Garrett, Zoe
    Stevens, Andrew
    LANCET ONCOLOGY, 2011, 12 (01): : 16 - 17
  • [46] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Akira Sawaki
    Yasuo Ohashi
    Yasushi Omuro
    Taroh Satoh
    Yasuo Hamamoto
    Narikazu Boku
    Yoshinori Miyata
    Hiroya Takiuchi
    Kensei Yamaguchi
    Yasutsuna Sasaki
    Tomohiro Nishina
    Atsushi Satoh
    Eishi Baba
    Takao Tamura
    Takashi Abe
    Kiyohiko Hatake
    Atsushi Ohtsu
    Gastric Cancer, 2012, 15 : 313 - 322
  • [47] Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis
    Xu, Ting
    Wang, Xicheng
    Xin, Ying
    Wang, Zhenghang
    Gong, Jifang
    Zhang, Xiaotian
    Li, Yanyan
    Ji, Congcong
    Sun, Yu
    Zhao, Feilong
    Huang, Depei
    Bai, Yuezong
    Li, Jian
    Shen, Lin
    CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 626 - 635
  • [48] Trastuzumab-based treatment of HER2-positive metastatic gastric cancer
    Dogan, I.
    Karabulut, S.
    Tastekin, D.
    Paksoy, N.
    Sakar, B.
    Vatansever, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S205 - S205
  • [49] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Sawaki, Akira
    Ohashi, Yasuo
    Omuro, Yasushi
    Satoh, Taroh
    Hamamoto, Yasuo
    Boku, Narikazu
    Miyata, Yoshinori
    Takiuchi, Hiroya
    Yamaguchi, Kensei
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Satoh, Atsushi
    Baba, Eishi
    Tamura, Takao
    Abe, Takashi
    Hatake, Kiyohiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2012, 15 (03) : 313 - 322
  • [50] Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study
    Nakamura, Yoshiaki
    Mizuno, Nobumasa
    Sunakawa, Yu
    Hamilton, Erika P.
    Hayashi, Hidetoshi
    Kim, Seung Tae
    Lee, Keun-Wook
    Monk, Bradley J.
    Nguyen, Danny
    Okines, Alicia Frances Clare
    O'Malley, David M.
    Pohlmann, Paula R.
    Reck, Martin
    Yu, Evan Y.
    Groisberg, Roman
    Ramos, Jorge
    Tan, Qianwen
    Stinchcombe, Tom
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345